# US 2019/0375860 A1 · Modified carbohydrates, compositions comprising the same, and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375860 A1
- Document ID: US20190375860A1
- Status: Published application
- Kind: A1
- Application number: 16/311,992
- Filed: 2017-06-30
- Published: 2019-12-12
- Earliest claimed: 2016-07-01
- Assignees: Wake Forest University Health Sciences; Wake Forest University
- Applicants: Wake Forest University Health Sciences; Wake Forest University
- Inventors: Mark E. WELKER; Emmanuel C. OPARA; Surya R. BANKS; Amber N. WEISSENENFLUH
- Web page: https://patentgrep.com/patent/US20190375860A1

## CPC

- C08B 37/0084: {Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates}
- A61K 31/734: Alginic acid
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6903: {the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel}
- C08L 5/04: Alginic acid; Derivatives thereof
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Modified alginates are described herein along with hydrogels comprising the same. A modified alginate may be prepared by reacting alginate and an aromatic compound (e.g., an aromatic amine) and/or pH sensitive compound. The modified alginates, hydrogels, and/or methods described herein may be used to coat and/or encapsulate at least a portion of a bioactive substance, optionally for oral delivery in humans and other animals.

## Claims

### Claim 1

A compound comprising at least one unit having a structure of Formula I:
wherein
Y is absent or a C1-C4 alkyl or C1-C4 alkenyl;
R1 is each independently selected from the group consisting of —H, —OH, —NH2, —COOH,
—NO2, —CN, —Br, —Cl, —F, —C1-C6 alkylhalide, unsubstituted or substituted —C1-C6 alkyl, unsubstituted or substituted —C1-C6 alkenyl, —SO2H, —SO3H, —COCH3, —Si(OH)3, —SO2NH2, —PO(OR′)2, and —B(OH)2, wherein R′ is unsubstituted or substituted alkyl, alkenyl, alkynyl, or aryl;
n is from 1 to 1,000,000; and
o is 0, 1, 2, 3, 4, or 5.

### Claim 2

A compound comprising at least one unit having a structure of Formula II:
wherein
Y is absent or a C1-C4 alkyl or C1-C4 alkenyl;
R1 is each independently selected from the group consisting of —H, —OH, —NH2, —COOH,
—NO2, —CN, —Br, —Cl, —F, —C1-C6 alkylhalide, unsubstituted or substituted —C1-C6 alkyl, unsubstituted or substituted —C1-C6 alkenyl, —SO2H, —SO3H, —COCH3, —Si(OH)3, —SO2NH2, —PO(OR′)2, and —B(OH)2, wherein R′ is unsubstituted or substituted alkyl, alkenyl, alkynyl, or aryl;
n is from 1 to 1,000,000; and
o is 0, 1, 2, 3, 4, or 5.

### Claim 3 (depends on 1)

The compound of claim 1, wherein at least one R1 is selected from the group consisting of —OH, —NH2, —COOH, —NO2, —CN, —Br, —Cl, —F, —C1-C6 alkylhalide, unsubstituted or substituted —C1-C6 alkyl, unsubstituted or substituted —C1-C6 alkenyl, —SO2H, —SO3H, —COCH3, —Si(OH)3, —SO2NH2, —PO(OR′)2, and —B(OH)2, and wherein R′ is unsubstituted or substituted alkyl, alkenyl, alkynyl, or aryl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein at least one R1 is in the para position and is selected from the group consisting of —OH, —NH2, —COOH, —NO2, —CN, —Br, —Cl, —F, —C1-C6 alkylhalide, unsubstituted or substituted —C1-C6 alkyl, unsubstituted or substituted —C1-C6 alkenyl, —SO2H, —SO3H, —COCH3, —Si(OH)3, —SO2NH2, —PO(OR′)2, and —B(OH)2, and wherein R′ is unsubstituted or substituted alkyl, alkenyl, alkynyl, or aryl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein at least one R1 has a pKa in a range of about 3 to about 6 or about 4 to about 4.5.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound comprises at least one pH sensitive functional group.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is prepared by reacting alginate with a reactant.

### Claim at position 8

-9. (canceled)

### Claim 10 (depends on 7)

The compound of claim 7, wherein the alginate is an oxidized alginate.

### Claim at position 10

-12. (canceled)

### Claim 13 (depends on 7)

The compound of claim 7, wherein the reactant is incorporated into the alginate in an amount of about 1% to about 15% of the polysaccharide units of the alginate.

### Claim 14 (depends on 7)

The compound of claim 7, wherein at least 90% or 95% of the reactant is chemically bond to the alginate.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound comprises an alginate backbone.

### Claim 16 (depends on 1)

A hydrogel comprising the compound of claim 1, wherein the compound is present in the hydrogel in an amount of about 0.1% to about 10% w/v of the hydrogel.

### Claim 17 (depends on 16)

The hydrogel of claim 16, wherein the hydrogel is cross-linked.

### Claim 18 (depends on 16)

The hydrogel of claim 16, wherein the hydrogel further comprises a bioactive substance.

### Claim 19 (depends on 18)

The hydrogel of claim 18, wherein the bioactive substance is uniformly distributed within the hydrogel.

### Claim 20

(canceled)

### Claim 21 (depends on 16)

The hydrogel of claim 16, wherein the hydrogel further comprises a divalent cation in an amount of about 0.1 mmol to about 1 mmol.

### Claim 22 (depends on 16)

The hydrogel of claim 16, wherein the hydrogel has an elastic modulus in a range of 1 or 5 kPa to about 15 or 20 kPa.

### Claim 23 (depends on 16)

The hydrogel of claim 16, wherein the hydrogel is in the form of a bead, microcapsule, and/or pellet.

### Claim 24 (depends on 16)

A method of treating a subject, the method comprising administering a hydrogel of claim 16 to a subject, wherein the hydrogel comprises at least one bioactive substance, thereby treating the subject.

### Claim 25 (depends on 16)

A method of increasing the stability and/or shelf life of a bioactive substance, the method comprising providing a hydrogel of claim 16, wherein the hydrogel comprises at least one bioactive substance, thereby increasing the stability and/or shelf life of the bioactive substance.

### Claim 26

(canceled)
